The investment reflects AceON’s continued focus on high-potential, technology-driven startups emerging from its acceleration programmes. JST 3D develops artificial intelligence solutions that transform standard CT scans into highly accurate, interactive 3D models within minutes — significantly improving surgical planning and diagnostic precision.
AI Transforming Surgical Preparation
JST’s core product applies advanced AI algorithms to medical imaging, converting traditional 2D CT scans into detailed 3D reconstructions. The solution supports both radiologists and surgeons by enhancing the visualization of anatomical structures and improving decision-making before complex procedures.
The practical application of the technology has already been demonstrated in clinical settings. In October 2025, JST’s software was used by three head surgeons during a live “Urological Robotics” masterclass, where a real kidney surgery was performed based on the company’s 3D reconstructions and technical input.
Launched commercially in November 2025, JST has already secured multiple paying customers in Italy across both private and public healthcare institutions. To date, more than 20 3D reconstructions have been delivered for academic partners and commercial clients.
Strong Academic and Technological Partnerships
The company is currently finalising a strategic partnership with two leading Italian academic centres. The collaboration will provide JST with access to significant volumes of imaging data to further train and enhance its AI models. In addition to technical development, the partnership will support clinical validation, scientific research, and broader commercialisation efforts.
JST has also partnered with global technology leaders, including Google for Startups and NVIDIA, which provide infrastructure support and strategic guidance to strengthen the computational capacity behind the AI engine.
Founding Team Combining Tech, Finance and Legal Expertise
The founding team brings together expertise across technology, economics, and regulatory frameworks. Giacomo Gaglione previously held managerial roles in strategic consultancy focused on cloud computing, machine learning, and AI applications in production processes. At JST, he leads operations and algorithm development. Simone Macchi brings academic and professional experience in economics and finance, with a background spanning both public and private sector financial analysis. Alberto Regalia, a company lawyer, has conducted research on legal aspects of technological innovation within the healthcare sector.
This multidisciplinary foundation positions JST at the intersection of AI development, healthcare operations, and regulatory compliance — a critical combination in medical technology innovation.
European Expansion Ahead
Currently operating in Italy, JST is preparing to expand into additional European markets throughout 2026, initially targeting academic centres and healthcare institutions in Central and Northern Europe. Pilot collaborations are expected to serve as entry points into these new markets.
Looking ahead, JST plans to broaden its AI model to cover additional organs and introduce an automated medical reporting feature that generates a preliminary diagnostic draft for surgeons based on imaging data.
Future development also includes integration with augmented and virtual reality technologies, as well as robotics systems, further enhancing surgical precision and intraoperative navigation.
Backed by an Experienced Investment Committee
The decision to invest was led by AceON’s Investment Committee, comprising Ján Kasper, Co-founder & Managing Partner at ZAKA VC, Peter Pašek, Managing Director & Partner at Accace Slovakia, Andrej Petrus, Head of Investment Committee & Partner at ZAKA VC, and Ján Búza, Partner at ZAKA VC.
With this third investment, AceON Accelerator continues to strengthen its portfolio of early-stage startups focused on deep tech and applied AI solutions with tangible real-world impact.
